Trophoblastic Disease Research
BackgroundSheffield is one of the two UK Centres treating trophoblastic tumours. The Sheffield Trophoblastic Screening and Treatment Centre covers a population of over 22 million from the North of England and North Wales. Around 600 women each year are registered in Sheffield following the diagnosis of a molar pregnancy. Therefore, there is a wealth of clinical, biochemical and histopathological date available for research.
As well as the Sheffield GTN team developing research projects we also combine with the other two centres in the UK - Charing Cross Hospital and Ninewells Hospital to develop joint projects.
Every two years the Sheffield Team attends the International Society for the Study of Trophoblastic Disease (ISSTD) Conference where research from across the globe is discussed
A recent initiative of which Sheffield is part, is an European group (European Organisation for Treatment of Trophoblastic Disease - EOTTD) formed to develop optimum treatment for GTN patients
In order to extend and focus our research we have defined three main themes - aimed broadly at:
- assessing best practice in clinical management
- helping understand the aetiology
- evaluating long-term physical and psychological morbidity
Recently completed projects
- Predicting gestational trophoblastic neoplasia (GTN): Is urine hCG the answer?
- Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease.
- Screening for central nervous system disease in metastatic gestational trophoblastic neoplasia
- A conservative approach in persistent low-level elevation of serum beta-human chorionic gonadotropin following chemotherapy for gestational trophoblastic neoplasia
Full list of publications from the last 5 years